Results 161 to 170 of about 29,245 (221)

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [PDF]

Front Immunol
Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, He P, Liu R, Zhang J, Wang K, Han R, Huangfu H.   +11 more
europepmc   +1 more source

Design, synthesis, and antibacterial assessment of a new series of ciprofloxacin-based compounds as possible dual DNA gyrase/topoisomerase IV inhibitors. [PDF]

Sci Rep
Al-Wahaibi LH, Alzahrani HA, Bräse S, Youssif BGM, Hisham M.   +4 more
europepmc   +1 more source

TOP1 and TOP2 complementarily maintain DNA replication fork progression in vertebrates. [PDF]

J Biol Chem
Umemura K, Ooka M, Sojo M, Seki M, Xia M, Hirota K, Abe T.   +6 more
europepmc   +1 more source

Processing of DNA Topoisomerase II-DNA-Protein Crosslinks Associated With Anticancer Drugs. [PDF]

Genes Cells
Sakasai R, Iwabuchi K.
europepmc   +1 more source

A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review. [PDF]

Cancer Med
Kotian N, Reddy Y, Pai P, Sundara BK.
europepmc   +1 more source

1,3,4-Oxadiazole derivatives: targeting multiple bacterial pathways. [PDF]

RSC Med Chem
Gupta P, Verma S, Narang R, Sharma B, Singh V, Lal S.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Topoisomerase II inhibitors in AML: past, present, and future

Expert Opinion on Pharmacotherapy, 2019
Introduction: Topoisomerase II inhibitors have long been used in the frontline and as salvage therapy for AML, with daunorubicin and idarubicin being prototypical agents in this therapeutic class, classically in combination with nucleoside analogs, e.g. cytarabine.
Minas P Economides, Deborah Mccue, Gautam Borthakur   +2 more
exaly   +3 more sources

Topoisomerase II inhibitors

Update on Cancer Therapeutics, 2003
Abstract This article reviews the mechanism of action, toxicity, pharmacology and clinical use of antineoplastic agents that inhibit the enzyme, topoisomerase II. Information presented in the medical and scientific literature in the past 3 years is especially highlighted.
JaNae M, Clapp, Kenneth R, Hande
openaire   +4 more sources